Related Experiment Video

Updated: Apr 7, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Sphingosine kinase 1 as an anticancer therapeutic target

Ying Gao1, Fei Gao2, Kan Chen3

  • 1Department of Radiotherapy Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.

Drug Design, Development and Therapy
|July 8, 2015
PubMed

Insights

Elevated sphingosine kinase 1 (SK1) promotes cancer progression and drug resistance. Inhibiting SK1 and its signaling pathway offers a promising strategy to overcome chemotherapy resistance in oncology.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Chemotherapeutic resistance is a significant obstacle in cancer treatment.
  • Elevated sphingosine kinase 1 (SK1) levels correlate with poor prognosis and may drive resistance.
  • The sphingosine kinase/sphingosine-1-phosphate/sphingosine-1-phosphate receptor (SK/S1P/S1PR) pathway is involved in cancer progression and drug resistance.

Purpose of the Study:

  • To review the role of the SK/S1P/S1PR signaling pathway in cancer.
  • To summarize the development of SK1 inhibitors for cancer therapy.
  • To highlight the potential of targeting this pathway to overcome drug resistance.

Main Methods:

  • Literature review of studies on SK/S1P/S1PR signaling in cancer.
  • Analysis of research on SK1 overexpression and its link to chemotherapeutic resistance.
  • Compilation of data on the efficacy and development of SK1 inhibitors.

Main Results:

  • The SK/S1P/S1PR pathway is implicated in various cancer types and drug resistance.
  • SK1 overexpression is a marker of poor prognosis and contributes to treatment failure.
  • Targeting SK1 presents a viable strategy for enhancing chemotherapy efficacy.

Conclusions:

  • The SK/S1P/S1PR pathway is a critical regulator of cancer cell behavior and drug response.
  • SK1 is a potential therapeutic target for overcoming chemotherapeutic resistance.
  • Further development of SK1 inhibitors is warranted for effective cancer treatment.
Keywords:
S1PS1PRcancerinhibitorssphingosine kinase 1therapy

More Related Videos

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

4.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K